127 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 127 shares of the company’s stock, valued at approximately $52,000.

A number of other large investors also recently added to or reduced their stakes in the company. Westwind Capital lifted its stake in Medpace by 800.1% during the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock worth $156,886,000 after acquiring an additional 338,610 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Medpace by 195.2% during the fourth quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock worth $143,162,000 after purchasing an additional 308,816 shares in the last quarter. Findlay Park Partners LLP purchased a new position in shares of Medpace in the first quarter valued at approximately $90,247,000. Clearbridge Investments LLC grew its holdings in shares of Medpace by 302.4% in the first quarter. Clearbridge Investments LLC now owns 260,411 shares of the company’s stock valued at $105,245,000 after purchasing an additional 195,698 shares in the last quarter. Finally, Norges Bank purchased a new stake in Medpace during the 4th quarter worth approximately $59,163,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Up 2.0 %

Shares of MEDP opened at $351.67 on Monday. The company has a market capitalization of $10.90 billion, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77. The stock has a 50 day moving average price of $384.27 and a 200 day moving average price of $393.30.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. During the same quarter in the prior year, the business posted $1.93 EPS. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on MEDP shares. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Mizuho initiated coverage on Medpace in a report on Tuesday, May 28th. They set a “buy” rating and a $435.00 price target on the stock. Deutsche Bank Aktiengesellschaft reduced their price target on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. Truist Financial started coverage on Medpace in a research report on Thursday, August 1st. They set a “hold” rating and a $415.00 price objective for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $423.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.